Omnicell, Inc. (NASDAQ:OMCL – Free Report) – Analysts at Zacks Research increased their Q1 2025 EPS estimates for shares of Omnicell in a research note issued on Tuesday, October 1st. Zacks Research analyst U. Biswas now expects that the company will earn $0.14 per share for the quarter, up from their prior estimate of $0.13. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q1 2026 earnings at $0.29 EPS and FY2026 earnings at $0.73 EPS.
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 EPS.
View Our Latest Analysis on Omnicell
Omnicell Stock Up 2.1 %
Omnicell stock opened at $42.39 on Thursday. The company’s 50 day simple moving average is $42.08 and its 200 day simple moving average is $33.28. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $46.05. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -92.15, a PEG ratio of 47.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after acquiring an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after acquiring an additional 228,093 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Omnicell during the first quarter valued at approximately $684,000. Finally, Cadian Capital Management LP bought a new position in shares of Omnicell during the fourth quarter valued at approximately $2,446,000. Institutional investors own 97.70% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
- Five stocks we like better than Omnicell
- Insider Buying Explained: What Investors Need to Know
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Trading Stocks: RSI and Why it’s Useful
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why Invest in High-Yield Dividend Stocks?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.